Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide

Authors Minze M, Chastain L

Received 1 October 2015

Accepted for publication 25 February 2016

Published 29 March 2016 Volume 2016:12 Pages 471—478

DOI https://doi.org/10.2147/TCRM.S73579

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 6

Editor who approved publication: Professor Garry Walsh

Molly G Minze,1 Lisa M Chastain2

1School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, 2Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA

Abstract: The global burden of type 2 diabetes is estimated to currently affect over 350 million people worldwide and is anticipated to continue increasing over the next 20 years. Current treatment guidelines recommend the choice of pharmacotherapy based upon patient-specific parameters, with combination therapy for patients with a hemoglobin A1c level ≥9%. A new combination therapy of insulin degludec + liraglutide provides a long-acting basal insulin with a glucagon-like peptide agonist. In clinical trials, this combination product has reduced hemoglobin A1c and fasting plasma glucose more than the individual agents alone. Further advantages observed with this combination include weight loss and decrease in hypoglycemia compared to basal insulin alone.

Keywords: insulin degludec, liraglutide, type 2 diabetes, basal insulin, glucagon-like peptide agonist, injectable therapies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]